Ideas For Now-
- Thread starter stonedinvestor
- Start date
Stoney...
Hey I like the DTEA.
They need a CBD-infused product line.
When they announce that, its off to the races again.
Lots of small players.
https://www.healthmj.com/cbd/best-cbd-drinks/#Best_CBD_Tea_Blends_in_2020
They can bury these guys using that cash-store for marketing.
Lets see what happens.
Good find.
Well, I guess there's a big player too.
But that says a lot. Follow the money.
AB InBev Will Sell CBD-Infused Tea in Canada
Author of the article:
Bloomberg News
Jacqueline Thorpe
Publishing date:
Dec 11, 2019 • • 2 minute read
(Bloomberg) — The world’s biggest brewer will kick off its push into cannabis-infused beverages with a lineup of flavored teas — Lavender Chamomile, Vanilla Rooibos and Peach Ginger Green.
The “Everie” teas will contain 98% pure cannabidiol, the non-psychotropic ingredient in cannabis, with only a trace — 0.05 milligrams — of THC, the component that gets you high. They will be sold through Fluent Beverages, a joint venture between Anheuser-Busch InBev NV’s Labatt Breweries of Canada and pot company Tilray Inc.’s High Park Co.
The drinks will hit the shelves after pot edibles and beverages become legal in Canada next week. Non-alcoholic sparkling beverages will follow early in 2020, the company said. AB InBev, based in Leuven, Belgium, sells Budweiser, the top-selling beer in Canada.
“The products we’ll be launching through Fluent are CBD only,” Kyle Norrington, president of Labatt Breweries of Canada, said in an interview at Bloomberg’s office in Toronto. For now, AB InBev doesn’t plan to move into THC-focused beverages, and it won’t be selling the CBD drinks in the U.S. where cannabis remains illegal at the federal level.
I knew you would. Cross your fingers and prey for me Earnings Tomorrow for Domo--
These guys are like your former SLACK
These guys are like your former SLACK
Well, not exactly. But I will "prey".
I should have peyed (sic) more attention to you buying this thing.
Did you look at this?
That said... stocks only go up.
DTEA .... now that one has potential long term. We need to watch the Canadian courts' rulings on how much they are gonna owe on all those cancelled leases.
A bad ruling and they are in a hurt locker.
I expect an announcement regarding CBD infused tea however. Easy move really. Especially now.
The CEO owns 54% of the shares. A $2 pop will put over 30MM in his pocket.
That'll cover the leases and then he sells the company (he's 89) for 15X FCF which is about $4.80/share.
Buy buy buy!
(but we gotta check the court dates)
(just in case)
I want to be a CEO!!! I've always wanted to be in the position of owning a s ton of one stock and really being marred to it and look--- you can go bankrupt and turn around and pocket 30MM if your bankrupt stock recovers to $2 only in America. i don't know whether to laugh or cry or buy..
Now listen up on DOMO -- Today would be the VERY worst DAY to Report several HIGH flyers like WDAY and a stock with almost the same symbol as DOMO (scared the crap out of me) Mongo I think anyway everything is DOWN people are not satisified.... CROWDstrike or source whatever DOWN. However DOMO MAY report at the end of the day the CC is at 17:00 EST???
I'm at a loss but listen up it's a risk worth taking I think. These guys are supposed to lose money I have to check maybe 5 cents.... WHAT if they come in EVEN or even up! It could happen because the Pandemic has not hurt this company and they are rolling out some sort of work from home solution to whatever they do... Yea I don't know-- It's Cloud based.
Akebia shares halted pending news-! OH NO!!!!!
Sep. 3, 2020 7:01 AM ET|About:Akebia Therapeutics (NASDAQ:AKBA) pending the release of news.... Oh folks dear stoney has paid dearly over the years for holding on to this HUGE loser in his account... would the gods of fortune look upon me today in a favorable light?
Now listen up on DOMO -- Today would be the VERY worst DAY to Report several HIGH flyers like WDAY and a stock with almost the same symbol as DOMO (scared the crap out of me) Mongo I think anyway everything is DOWN people are not satisified.... CROWDstrike or source whatever DOWN. However DOMO MAY report at the end of the day the CC is at 17:00 EST???
I'm at a loss but listen up it's a risk worth taking I think. These guys are supposed to lose money I have to check maybe 5 cents.... WHAT if they come in EVEN or even up! It could happen because the Pandemic has not hurt this company and they are rolling out some sort of work from home solution to whatever they do... Yea I don't know-- It's Cloud based.
Akebia shares halted pending news-! OH NO!!!!!
Sep. 3, 2020 7:01 AM ET|About:Akebia Therapeutics (NASDAQ:AKBA) pending the release of news.... Oh folks dear stoney has paid dearly over the years for holding on to this HUGE loser in his account... would the gods of fortune look upon me today in a favorable light?
Last edited:
Analysts covering Domo have modeled for quarterly EPS loss of $0.5 on revenue of $49.03 million. In the same quarter last year, Domo posted a loss of $0.96 per share on sales of $41.66 million.
Now I'm just guessing here/// But I'd say DOMO's Rev may be $55 mil plus.... not $49 mil.....
What that does to EPS is anyone's guess with the tricks and cost of acquisitions etc......
Now do they report at the open? I don't know I'm so scared I can't even look... People are in a selling mood but what if we can hold on til the end of the day? And then report?
---> Gates-backed vehicle battery supplier going public through SPAC deal, CNBC says
?
Only stoney... This is what scared me so--Momo reports Q2 EPS 43c, consensus 43c »
thank goodness we bought DOMO. Often I'm on the worng side of these near names... this time I may have the winner...
Now I'm having my one letter problem the other way with my testers.... the big new winner sounds so close to mine but it's different!-- You rememebr FLDM well..... here comes FLGT... they got the NYC contract for schools!
Fulgent COVID-19 testing will 'remain robust,' says Piper Sandler 05:01 FLGT Piper Sandler analyst Steven Mah has increased confidence in Fulgent Genetics following recent meetings with management. The analyst keeps an Overweight rating on the shares with a $73 price target. Fulgent's sub-24 hour TAT and end-to-end technology platform is underappreciated, and the company is increasing share in COVID-19 testing, Mah tells investors in a research note. Further, Fulgent has expanded outside of California, with "big wins" in New York City and Miami-Dade county, says the analyst. He believes the company's COVID-19 testing will "remain robust" for the next few years.
It's wack -a-mole-time in testing... $73 price target I should add the stk is $28!
Back To Domo, he's a nice guy has his arm in the air and kids love to cuddle with him.
-- Now one thing I noticed is all the price targets are under or right around where it is. Finally a stk that has not been over discovered nor are the analysts light years behind it seems to be properly judged and projected. We don't want catch up and a stock well above where it should be... that's dangerous.
Needham analyst Jack Andrews has the most recent report. He was behind a bit & raised the firm's price target on Domo to $47 from $38 and keeps a Buy rating. No big deal $47 is actually a low target the stk is $44 already one could see this as a negative but in this overcharged go go environment I don't. I may be wrong but I don't.
Q2 results this Thursday. But when? This is one that you want to wait for the conference call... because- The company has recently launched a return to work application,
That sounds like an Idea For Now! Although what that application is I have no idea. Has there not been a good response for tech co's that do that? That's the argument of the Needham analyst and then there's a whole bunch with PT's under the price so if we could turn this earnings wise I would guess the new level for DOMO would be $55. ST and eventually mid $70's.
Andrews the Needham analyst adds that Domo management has indicated that momentum during the pandemic is "surprisingly constructive", while the trends within the business deals "appear positive".
Once again glass half full I guess but "Surprisingly " leads me to hope... for a surprise earnings wise! Common On Board DOMO!
LET'S DO THIS!
Now I'm just guessing here/// But I'd say DOMO's Rev may be $55 mil plus.... not $49 mil.....
What that does to EPS is anyone's guess with the tricks and cost of acquisitions etc......
Now do they report at the open? I don't know I'm so scared I can't even look... People are in a selling mood but what if we can hold on til the end of the day? And then report?
---> Gates-backed vehicle battery supplier going public through SPAC deal, CNBC says
?
Only stoney... This is what scared me so--Momo reports Q2 EPS 43c, consensus 43c »
thank goodness we bought DOMO. Often I'm on the worng side of these near names... this time I may have the winner...
Now I'm having my one letter problem the other way with my testers.... the big new winner sounds so close to mine but it's different!-- You rememebr FLDM well..... here comes FLGT... they got the NYC contract for schools!
Fulgent COVID-19 testing will 'remain robust,' says Piper Sandler 05:01 FLGT Piper Sandler analyst Steven Mah has increased confidence in Fulgent Genetics following recent meetings with management. The analyst keeps an Overweight rating on the shares with a $73 price target. Fulgent's sub-24 hour TAT and end-to-end technology platform is underappreciated, and the company is increasing share in COVID-19 testing, Mah tells investors in a research note. Further, Fulgent has expanded outside of California, with "big wins" in New York City and Miami-Dade county, says the analyst. He believes the company's COVID-19 testing will "remain robust" for the next few years.
It's wack -a-mole-time in testing... $73 price target I should add the stk is $28!
Back To Domo, he's a nice guy has his arm in the air and kids love to cuddle with him.
-- Now one thing I noticed is all the price targets are under or right around where it is. Finally a stk that has not been over discovered nor are the analysts light years behind it seems to be properly judged and projected. We don't want catch up and a stock well above where it should be... that's dangerous.
Needham analyst Jack Andrews has the most recent report. He was behind a bit & raised the firm's price target on Domo to $47 from $38 and keeps a Buy rating. No big deal $47 is actually a low target the stk is $44 already one could see this as a negative but in this overcharged go go environment I don't. I may be wrong but I don't.
Q2 results this Thursday. But when? This is one that you want to wait for the conference call... because- The company has recently launched a return to work application,
That sounds like an Idea For Now! Although what that application is I have no idea. Has there not been a good response for tech co's that do that? That's the argument of the Needham analyst and then there's a whole bunch with PT's under the price so if we could turn this earnings wise I would guess the new level for DOMO would be $55. ST and eventually mid $70's.
Andrews the Needham analyst adds that Domo management has indicated that momentum during the pandemic is "surprisingly constructive", while the trends within the business deals "appear positive".
Once again glass half full I guess but "Surprisingly " leads me to hope... for a surprise earnings wise! Common On Board DOMO!
LET'S DO THIS!
--ShotSpotter assumed with an Outperform at Northland 07:54 SSTI Northland analyst Michael Latimore raised the firm's price target on ShotSpotter to $36 from $34 and keeps an Outperform rating on the shares as he assumed coverage of the stock. The analyst, who sees ShotSpotter having the leading gunshot detection technology and being "by far the leading provider in the space," thinks the company has addressed under 10% of its total available market opportunity.
Wow the short opportunity in AMRN was huge!
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
Oppenheimer analyst Leland Gershell is "more skeptical" that the District Court's ruling of invalidity of Amarin's Vascepa's patents will be overturned following yesterday's Federal Appeals Court hearing. Amarin shares closed Wednesday down 31%, or $2.22, to $5.04.
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
Oppenheimer analyst Leland Gershell is "more skeptical" that the District Court's ruling of invalidity of Amarin's Vascepa's patents will be overturned following yesterday's Federal Appeals Court hearing. Amarin shares closed Wednesday down 31%, or $2.22, to $5.04.
And now folks are saying $3 on a loss but wait... wil the " winner " be able to get enough high quality fish oil to sell...
Amarin shares have downside to $3 on patent loss, says Northland
An unfavorable Vascepa patent ruling from the Court of Appeals Federal Circuit can place the shares of Amarin in the $3 range, Northland analyst Carl Byrnes tells investors in a research note. However, a favorable ruling can take the shares above $25, adds the analyst. Amarin closed yesterday down 31% to $5.04 after oral arguments were heard in the patent appeal case. Prospects of a reversal for Amarin on appeal dampened yesterday to around 25%, Byrnes contends. Hikma provided "clear and convincing" evidence to support invalidating the six Amarin patents on the basis of obviousness, says the analyst. Nonethless, Byrnes still believes potential generic entrants would encounter problems in obtaining commercial quantities of FDA-grade icosapent ethyl. As such, even with potential generic competition, Vascepa can retain the "lion's share of the market," according to the analyst. Byrnes keeps an Outperform rating on Amarin with a $15 price target.!!!!!
This just got a whole lot more interesting....
Amarin shares have downside to $3 on patent loss, says Northland
An unfavorable Vascepa patent ruling from the Court of Appeals Federal Circuit can place the shares of Amarin in the $3 range, Northland analyst Carl Byrnes tells investors in a research note. However, a favorable ruling can take the shares above $25, adds the analyst. Amarin closed yesterday down 31% to $5.04 after oral arguments were heard in the patent appeal case. Prospects of a reversal for Amarin on appeal dampened yesterday to around 25%, Byrnes contends. Hikma provided "clear and convincing" evidence to support invalidating the six Amarin patents on the basis of obviousness, says the analyst. Nonethless, Byrnes still believes potential generic entrants would encounter problems in obtaining commercial quantities of FDA-grade icosapent ethyl. As such, even with potential generic competition, Vascepa can retain the "lion's share of the market," according to the analyst. Byrnes keeps an Outperform rating on Amarin with a $15 price target.!!!!!
This just got a whole lot more interesting....